Unknown

Dataset Information

0

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.


ABSTRACT: INTRODUCTION:Reliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients treated with everolimus. RESULTS:we found a linear correlation between everolimus exposure duration and BMI/weight decrease. Patients exhibiting >2 kg weight loss or >3% BMI decrease from baseline at the end of treatment (EOT) had a statistically significant improvement in PFS. Interestingly, a similar BMI/weight decrease within the first 8 weeks of therapy identified patients at higher risk of progression. PATIENTS AND METHODS:we performed a retrospective analysis of patients enrolled in the BALLET trial who progressed during the study. Primary end-point was progression-free survival (PFS). Secondary end-point was the identification of other predictors of response. CONCLUSION:A >3% weight loss at EOT is associated with better outcome in mBC patients treated with everolimus. On the contrary, a significant early weight loss represents a predictor of poor survival and could therefore be used as an early negative prognostic marker. As PI3K-inhibition also converges onto mTOR, these findings might extend to patients treated with selective PI3K inhibitors and warrant further investigation.

SUBMITTER: Corona SP 

PROVIDER: S-EPMC7289535 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.

Corona Silvia P SP   Giudici Fabiola F   Jerusalem Guy G   Ciruelos Eva E   Strina Carla C   Sirico Marianna M   Bernocchi Ottavia O   Milani Manuela M   Dester Martina M   Ziglioli Nicoletta N   Barbieri Giuseppina G   Cervoni Valeria V   Montemurro Filippo F   Generali Daniele D  

Oncotarget 20200609 23


<h4>Introduction</h4>Reliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients treated with everolimus.<h4>Results</h4>we found a linear correlation between everolimus exposure duration and BMI/weight decrease. Patients exhibiting >2 kg weight loss or >3% BMI decrease from baseline at the end of treatment (EOT) had a stati  ...[more]

Similar Datasets

| S-EPMC6761348 | biostudies-literature
| S-EPMC4571987 | biostudies-literature
| S-EPMC8018320 | biostudies-literature
| S-EPMC5058473 | biostudies-literature
| S-EPMC8329161 | biostudies-literature
| S-EPMC3023787 | biostudies-literature
| S-EPMC5725056 | biostudies-literature
| S-EPMC6515626 | biostudies-literature
| S-EPMC5652899 | biostudies-literature
| S-EPMC3499375 | biostudies-literature